Incidence of cervical, breast and colorectal cancers between 2010 and 2015 in people living with HIV in France.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2022
2022
Historique:
received:
04
05
2021
accepted:
23
11
2021
entrez:
25
3
2022
pubmed:
26
3
2022
medline:
15
4
2022
Statut:
epublish
Résumé
We aimed to evaluate the incidence rates between 2010 and 2015 for invasive cervical cancer (ICC), breast cancer (BC), and colorectal cancer (CRC) in people living with HIV (PLWH) in France, and to compare them with those in the French general population. These cancers are targeted by the national cancer-screening program. This is a retrospective study based on the longitudinal data of the French Dat'AIDS cohort. Standardized incidence ratios (SIR) for ICC and BC, and incidence rates for all three cancers were calculated overall and for specific sub-populations according to nadir CD4 cell count, HIV transmission category, HIV diagnosis period, and HCV coinfection. The 2010-2015 CRC incidence rate was 25.0 [95% confidence interval (CI): 18.6-33.4] per 100,000 person-years, in 44,642 PLWH (both men and women). Compared with the general population, the ICC incidence rate was significantly higher in HIV-infected women both overall (SIR = 1.93, 95% CI: 1.18-3.14) and in the following sub-populations: nadir CD4 ≤ 200 cells/mm3 (SIR = 2.62, 95% CI: 1.45-4.74), HIV transmission through intravenous drug use (SIR = 5.14, 95% CI: 1.93-13.70), HCV coinfection (SIR = 3.52, 95% CI: 1.47-8.47) and HIV diagnosis before 2000 (SIR = 2.06, 95% CI: 1.07-3.97). Conversely, the BC incidence rate was significantly lower in the study sample than in the general population (SIR = 0.56, 95% CI: 0.42-0.73). The present study showed no significant linear trend between 2010 and 2015 in the incidence rates of the three cancers explored in the PLWH study sample. Specific recommendations for ICC screening are still required for HIV-infected women and should focus on sub-populations at greatest risk.
Sections du résumé
BACKGROUND
We aimed to evaluate the incidence rates between 2010 and 2015 for invasive cervical cancer (ICC), breast cancer (BC), and colorectal cancer (CRC) in people living with HIV (PLWH) in France, and to compare them with those in the French general population. These cancers are targeted by the national cancer-screening program.
SETTING
This is a retrospective study based on the longitudinal data of the French Dat'AIDS cohort.
METHODS
Standardized incidence ratios (SIR) for ICC and BC, and incidence rates for all three cancers were calculated overall and for specific sub-populations according to nadir CD4 cell count, HIV transmission category, HIV diagnosis period, and HCV coinfection.
RESULTS
The 2010-2015 CRC incidence rate was 25.0 [95% confidence interval (CI): 18.6-33.4] per 100,000 person-years, in 44,642 PLWH (both men and women). Compared with the general population, the ICC incidence rate was significantly higher in HIV-infected women both overall (SIR = 1.93, 95% CI: 1.18-3.14) and in the following sub-populations: nadir CD4 ≤ 200 cells/mm3 (SIR = 2.62, 95% CI: 1.45-4.74), HIV transmission through intravenous drug use (SIR = 5.14, 95% CI: 1.93-13.70), HCV coinfection (SIR = 3.52, 95% CI: 1.47-8.47) and HIV diagnosis before 2000 (SIR = 2.06, 95% CI: 1.07-3.97). Conversely, the BC incidence rate was significantly lower in the study sample than in the general population (SIR = 0.56, 95% CI: 0.42-0.73).
CONCLUSION
The present study showed no significant linear trend between 2010 and 2015 in the incidence rates of the three cancers explored in the PLWH study sample. Specific recommendations for ICC screening are still required for HIV-infected women and should focus on sub-populations at greatest risk.
Identifiants
pubmed: 35333883
doi: 10.1371/journal.pone.0261069
pii: PONE-D-21-14748
pmc: PMC8956191
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0261069Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
PLoS One. 2015 Jun 17;10(6):e0129550
pubmed: 26083524
AIDS. 2014 Mar 27;28(6):881-90
pubmed: 24300545
HIV Med. 2017 Mar;18(3):181-195
pubmed: 28967199
World J Gastroenterol. 2015 Dec 7;21(45):12896-953
pubmed: 26668515
Papillomavirus Res. 2018 Jun;5:46-58
pubmed: 29277575
J Acquir Immune Defic Syndr. 1999 Aug 1;21 Suppl 1:S34-41
pubmed: 10430217
PLoS One. 2010 Dec 16;5(12):e14349
pubmed: 21179547
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Int J Cancer. 1999 Jul 30;82(3):334-7
pubmed: 10399949
Biol Psychiatry. 2011 Mar 15;69(6):592-600
pubmed: 21195389
Eur J Cancer. 2012 Dec;48(18):3335-41
pubmed: 22766516
BMC Infect Dis. 2013 Oct 09;13:471
pubmed: 24106926
J Natl Cancer Inst. 2011 May 4;103(9):753-62
pubmed: 21483021
J Acquir Immune Defic Syndr. 2009 Dec;52(5):611-22
pubmed: 19770804
Br J Cancer. 2019 May;120(10):1015-1022
pubmed: 30988395
J Acquir Immune Defic Syndr. 2013 Aug 15;63(5):e163
pubmed: 24135779
J Acquir Immune Defic Syndr. 2008 Aug 1;48(4):485-90
pubmed: 18614916
Am J Infect Control. 2017 Sep 1;45(9):1050-1051
pubmed: 28732746
AIDS. 2006 Aug 1;20(12):1645-54
pubmed: 16868446
Int J Cancer. 2020 Feb 1;146(3):601-609
pubmed: 31215037
J Clin Pathol. 2002 Apr;55(4):244-65
pubmed: 11919208
N Engl J Med. 1998 Mar 26;338(13):853-60
pubmed: 9516219
J Acquir Immune Defic Syndr. 2013 Apr 1;62(4):405-13
pubmed: 23254153
Cancer. 2017 Apr 1;123(7):1202-1211
pubmed: 28117886
HIV Med. 2019 Mar;20(3):222-229
pubmed: 30693646
HIV Med. 2016 Sep;17(8):590-600
pubmed: 26890156
J Natl Cancer Inst. 2018 Sep 1;110(9):959-966
pubmed: 29529223
Cancer Epidemiol Biomarkers Prev. 2021 Mar;30(3):554-563
pubmed: 33310788
AIDS. 2016 Jun 19;30(10):1663-8
pubmed: 26950314
World J Surg Oncol. 2018 Jan 11;16(1):4
pubmed: 29325566
Curr Opin HIV AIDS. 2017 Jan;12(1):6-11
pubmed: 27749369
Top Antivir Med. 2014 Jun-Jul;22(3):660-5
pubmed: 25101532
J Natl Cancer Inst. 2015 Feb 06;107(4):
pubmed: 25663691
HIV Med. 2009 Sep;10(8):504-11
pubmed: 19486189
AIDS. 2009 May 15;23(8):875-85
pubmed: 19349851
J Natl Cancer Inst. 2003 Jul 16;95(14):1062-71
pubmed: 12865452
AIDS Care. 2014;26(6):716-22
pubmed: 24188387
Pan Afr Med J. 2017 Dec 04;28:287
pubmed: 29675121
Asian Pac J Cancer Prev. 2012;13(1):243-6
pubmed: 22502677
Curr Infect Dis Rep. 2014 Jun;16(6):406
pubmed: 24844467
JAMA. 2005 Mar 23;293(12):1471-6
pubmed: 15784870